Prevalence, symptom and severity of COVID 19 among permanent residents of Dhaka City
PDF

Keywords

COVID 19 pandemic
situation of COVID 19
second wave
Dhaka city
Bangladesh

How to Cite

Lasker, S. P., Shah Mahfuzur, . R., Jafurullah, M., Ansari, M. A. J., & Hossain, A. (2022). Prevalence, symptom and severity of COVID 19 among permanent residents of Dhaka City. HEALTH SCIENCES QUARTERLY, 2(2), 73-80. https://doi.org/10.26900/hsq.2.2.02

Abstract

A study was done on 385 people who survived from COVID 19 to assess the prevalence, symptom, and severity of COVID 19 of permanent residents of Dhaka city, Bangladesh during the second wave of corona manifestation. Data were collected purposively from a government and a private hospital, and general people taking treatment from home. A significant number of respondents took treatment from the Hospital during 2nd wave of COVID 19. Two-third of participants endured moderate (67.5%) type of suffering followed by mild (18.7%) and severe (13.8%) type of suffering. Most of the participants were married (88.8%) and female (51.2%). There was no significant difference between females and males suffering and the risk and severity of COVID 19 (p=694). Most of the participants (70%) had comorbidity. Time to recover from symptoms had significant relation with symptom patterns. One-third of the respondents (33%) required 4-7 days to recover from suffering. A little higher than a quarter (27.8%) recovered within 8 to 14 days and more than a quarter 105 (27.3%) recovered by 8-12 days respectively. Most of the respondents had a fever, cough, body ache and fatigue, sore throat, and breathing difficulty. Only (7.3%) had diarrhea (3.9%) and smell loss 13 (3.4%). People of permanent residence of Dhaka city suffered from COVID 19 irrespective of sex, education, professional status. They had comorbidity, required 8-14 days of hospitalization, and endured the moderate type of suffering of COVID-19.

https://doi.org/10.26900/hsq.2.2.02
PDF

References

Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy. 2020;5(6):1-3. https://doi.org/10.1186/s41256-020-00135-6

Munster VJ, Koopmans M, Doremalen VN, Riel VD and Wit DE. A novel coronavirus emerging in China. Key questions for impact assessment. N Engl J Med 2020; 382:692-694. https://doi.org/10.1056/NEJMp2000929

WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 ( Access on March 2020).

The Straits Times. Bangladesh confirms first three cases of coronavirus. https://www.straitstimes.com/asia/south-asia/bangladesh-confirms-first-three-cases-of-coronavirus ( Access on March 2020).

Worldometer. https://www.worldometers.info/coronavirus/ (Access on December 18, 2021).

Nazneen A, Sultana R, Rahman M, Rahman M, Qadri F, Rimi NA et al. Prevalence of COVID-19 in Bangladesh, April to October 2020—a cross-sectional study. IJID Regions. 2021;1: 92–99. https://doi.org/10.1016/j.ijregi.2021.10.003

Hossain I, Mullick AR, Khan MH, Halim KS, Aktaruzzaman MM, Nabi SG, et al. Comorbidity and its impact on COVID-19 affected patients in COVID-19 dedicated hospital of Bangladesh. Bangladesh Med J. 2021;49(1):19-25. https://doi.org/10.3329/bmj.v49i1.52585

Siam MHB, Hasan MM, Tashrif SM, Khan MHR, Raheem E, Hossain MS. Insights into the first seven-months of COVID-19 pandemic in Bangladesh: lessons learned from a high-risk country. Heliyon. 2021; 7(6):1-10. https://doi.org/10.1016/j.heliyon.2021.e07385.

Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: Focus on severity and mortality. Front Public Health. 2020;8(152). doi:10.3389/fpubh.2020.00152

Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303-310. https://www.doi:10.1016/j.dsx.2020.04.004

Çilekar S, Balcı, A, İbrahim CG. Is Covid-19 responsible for asthma and COPD exacerbations? . Health Sciences Quarterly. 2022;2(1):17-25. https://doi.org/10.26900/hsq.2.1.03

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW et al . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020; 323(20):2052-2059. http://doi.org/10.1001/ jama.2020.6775

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. IJID. 2020;94: 91–95. https://doi.org/10.1016/j.ijid.2020.03.01

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818. http://doi.org/10.1001/jamacardio.2020.1017

Pablo GB, Valerio C, and, Ericka R. Gender Differences in altruism on Mechanical

Turk: Expectations and actual behaviour. Economics Letters. 2018; 170:19-23. https://doi.org/10.1016/j.econlet.2018.05.022

WHO. Gender and COVID-19. World Health Organization; 2020 advocacy brief, 14 May 2020 https://apps.who.int/iris/ bitstream/handle/10665/332080/WHO-2019-nCoV-Advocacy_brief-Gender-2020.1- eng.pdf?sequence=1&isAllowed=y (Access on December 14 2021)

Barua, U. K., Saha, S. K., Ghosh, D. K., & Ruble, M. M. K. Epidemiological study on bronchial asthma at Shaheed Suhrawardy Medical College Hospital, Dhaka. Journal of Shaheed Suhrawardy Medical College. 2013;5(2): 77–80. https://doi.org/10.3329/jssmc.v5i2.20759

Torres RM, Souza MDS, Coelho ACC, de Mello LM and Machado CZ. Association between asthma and Type 2 diabetes mellitus: Mechanisms and impact on asthma control—A Literature Review. Canadian Respiratory Journal. 2021; 1-13. https://doi.org/10.1155/2021/8830439

Rogala, B., Bożek, A., & Gluck, J. Is there a relationship between asthma and diabetes? The Journal of Asthma. 2020; 57(12): 1332–1338. https://doi.org/10.1080/02770903.2019.1652642

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2022 Holistence Publications

Downloads

Download data is not yet available.